(Q37144885)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

K Annecke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

M Schmitt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

U Euler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

M Zerm

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

D Paepke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

S Paepke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

C Thomssen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

N Harbeck

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

Advances in Clinical Chemistry

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

31-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

Regulation and interactions in the activation of cell-associated plasminogen

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Plasminogen activation at the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

1 reference

7 January 2021

The hemostatic system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Plasminogen activation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Old dogs and new tricks: proteases, inhibitors, and cell migration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Limited Prognostic Value of c-erbB-2 Compared to uPA and PAI-1 in Primary Breast Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Urokinase-type plasminogen activator antigen and early relapse in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2807%2900002-9

7 January 2021

10.1016/S0065-2423(07)00002-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18429492%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference